The Development of FLT3 Inhibitors in Acute Myeloid Leukemia




FLT3 mutations, generally associated with a poor prognosis, are found in approximately one-third of patients with acute myeloid leukemia (AML) and represent an attractive therapeutic target. FLT3 inhibitors undergoing clinical evaluation include first-generation relatively non-specific small molecules and second-generation compounds with higher potency and selectivity against mutant FLT3. Recently presented results from a prospective randomized clinical trial will likely lead to a change in the standard of care for younger patients with FLT3-mutated AML: addition of the multi-targeted FLT3 inhibitor midostaurin to standard induction and consolidation chemotherapy. Thus, personalized therapies for this subset of AML will soon be possible.


Key points








  • Patients with FMS-like tyrosine kinase 3 gene ( FLT3 )–in-frame internal tandem duplication (ITD)–positive mutant acute myeloid leukemia (AML) generally have a poor prognosis.



  • Midostaurin, a multitargeted kinase inhibitor, may soon be routinely added to chemotherapy in newly diagnosed mutant FLT3.



  • Newer, more-specific FLT3 inhibitors, including some that target both FLT3 -ITD and FLT3 –tyrosine kinase domain (TKD), are being aggressively evaluated.


Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Sep 14, 2017 | Posted by in HEMATOLOGY | Comments Off on The Development of FLT3 Inhibitors in Acute Myeloid Leukemia

Full access? Get Clinical Tree

Get Clinical Tree app for offline access